Yudu - Nanotimes January 2011

11-01 :: December 2010 / January 2011

nanotimes

Companies Facts

se materials. Holographic information “inscribed” onto photopolymers by exposing them to laser beams can subsequently be made visible by various means.

Thanks to these outstanding properties, the films can also be used to create holographic optical elements (HOEs) that can reproduce the optical functions of lenses, mirrors and prisms in a thin film, or even combine them with one another.

Equally impressive: Sunscreen sprays and lotions can benefit in a variety of ways when formulated with the polyurethane dispersion Baycusan®

C 1000 from

Bayer MaterialScience. Although the film-forming polymer itself does not contain any UV-absorbing components, it can boost the sun protection factor (SPF) of a formulation. New test results confirm the varied benefits of Baycusan®

neither cosolvents nor preservatives. It has been confirmed, for example, that Baycusan®

of its common stock and warrants to purchase up to approximately 5.3 million additional shares of its common stock. Each unit, consisting of one share of common stock and a warrant to purchase 0.50 of a share of common stock, was sold for a purchase price of $1.70, a premium to the closing price on the prior full trading day before the securities purchase agreements were signed.

C 1000, which contains C 1000 not

only shows an SPF-boosting effect in formulations that include the UVB filters octocrylene and ethyl- hexyl triazone, but significantly increases the SPF of formulations based on broadband UV filters such as bis-ethylhexyloxyphenol methoxyphenyl triazine (BEMT) and benzophenone-3. Baycusan®

C 1000

also acts as a stabilizing raw material for oil-in-water (O/W) emulsions.. http://www.bayermaterialscience.com

ioSante Pharmaceuticals, Inc. (NASDAQ: BPAX) closed a previously announced sale of an aggre-

gate of $18 million of securities in a registered direct offering. BioSante received net proceeds of appro- ximately $16.9 million after deducting placement agent fees and other offering expenses. BioSante sold an aggregate of approximately 10.6 million shares

The warrants to purchase additional shares are ex- ercisable immediately at an exercise price of $2.00 per share and will expire on December 29, 2015. All of the securities were offered pursuant to an effec- tive shelf registration statement. Proceeds from the transaction will be used for general corporate pur- poses, including BioSante’s LibiGel Phase III clinical study program. LibiGel remains the lead pharmaceu- tical product in the U.S. in active development for the treatment of hypoactive sexual desire disorder (HSDD) in menopausal women, and BioSante be- lieves that LibiGel has the potential to be the first product approved by the FDA for this common and unmet medical need.

Furthermore, BioSante Pharmaceuticals announced results of a survey of over 100 Obstetrician/Gyne- cologists and Primary Care Physicians regarding the need for an FDA-approved drug to treat a form of Female Sexual Dysfunction (FSD) known as Hypo- active Sexual Desire Disorder (HSDD). The multiple surveys, conducted independently for BioSante by Campbell Alliance Group, Inc., revealed sexual dys- function to be one of the most common complaints received in these doctors’ offices. The physicians described themselves as dissatisfied with the current lack of therapeutic options for HSDD, a loss of libido or sexual desire.